Loading
Life sciences · Journal article
Urology Practice · October 23, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
INTRODUCTION: Adequate bacillus Calmette-Guérin (BCG) therapy, as defined by the U.S. Food and Drug Administration (FDA), is widely used in clinical trial eligibility criteria and regulatory frameworks, yet its prognostic relevance in real-world practice remains incompletely understood. We evaluated the association between time-dependent completion of adequate BCG therapy and oncologic outcomes in patients with high-risk non-muscle-invasive bladder cancer (HR NMIBC). METHODS: This retrospective cohort study included 188 patients with treatment-naïve HR NMIBC treated with BCG. Adequate BCG therapy was defined according to FDA criteria, and patients were categorized according to the timing of achieving adequate BCG therapy. In a landmark analysis, Cox regression models were used to evaluate the effect of clinicopathologic characteristics and timing of adequate BCG therapy completion on conditional high-grade recurrence-free survival (HG-RFS). RESULTS: The proportion of patients completing adequate BCG therapy increased over time, reaching 61.7% by 6 months from induction initiation. Among patients included in the landmark analysis (n = 140), completion of adequate BCG therapy between 4 and 5 months after initiation of induction BCG was associated with significantly improved HG-RFS compared with completion by 4 months (hazard ratio 0.31, 95% confidence interval 0.12-0.79). CONCLUSIONS: Among patients who met FDA-defined adequate BCG criteria, completion of therapy between 4 and 5 months was associated with the most favorable oncologic outcomes observed in this cohort. These findings provide real-world context for current definitions of adequate BCG exposure and suggest that the temporal pattern of treatment delivery may be an important consideration when evaluating BCG-related outcomes.